Welcome to our dedicated page for Belite Bio news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Belite Bio, Inc. reports clinical and regulatory developments for tinlarebant, an oral investigational therapy for degenerative retinal diseases. The company focuses on Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration, with a program designed to reduce accumulation of bisretinoid toxins in the eye.
Recurring updates include DRAGON and DRAGON II Stargardt disease studies, PHOENIX geographic atrophy development, FDA interactions, scientific meeting presentations, investor-conference appearances, financial results, annual Form 20-F availability, and capital actions involving American Depositary Shares. Company news also covers corporate updates for a foreign private issuer whose securities trade under BLTE.
Belite Bio (BLTE) has successfully closed its initial public offering, selling 6 million American Depositary Shares (ADSs) at $6.00 each, accumulating gross proceeds of $36 million. An additional 900,000 ADSs may be purchased by underwriters. Principal shareholder Lin Bioscience invested $15 million in the offering. The ADSs are now listed on the Nasdaq Capital Market, trading under BLTE since April 29, 2022. The funds will support the Phase 3 clinical trial of LBS-008 for Stargardt disease, further development for dry AMD, and general corporate purposes.
Belite Bio (Nasdaq: BLTE) announced that LBS-008, an oral tablet for treating Stargardt disease (STGD1), has received Fast Track Designation from the FDA. This designation accelerates the development of drugs for serious conditions lacking approved treatments. The company is currently conducting a Phase 2 and a Phase 3 trial for STGD1, which affects around 30,000 patients in the U.S. This follows LBS-008's recognition as a rare pediatric disease and orphan drug in both the U.S. and Europe. The next data readout for the Phase 2 trial is anticipated in Q4 2022.